Skip to main content

About CRUK Scotland Institute

Find out what we do, how we do it and why we do what we do.

A person walks across a city street at sunset, with tall buildings lining the road on both sides.

Life in Glasgow

Find out about living and working in Glasgow and Scotland.

Our Research

Explore the science at CRUK Scotland Institute. Our research groups, the people who lead them, and how we work.

Operations

The teams and services that keep the Institute running and support our research.

Partners

The networks and organisations we work with to accelerate cancer research.

Careers & Study

Jobs, studentships and opportunities for students at every stage at our world-renowned cancer research institute.

Studentships

PhD opportunities at the Institute

Studentship Vacancies

Open studentships to apply for

Internships

For undergraduate and masters students

Dr Riccardo Mezzadra

Cancer-Immune Crosstalk

 

Tumours are complex ecosystems in which cancer cells constantly communicate with non-malignant cells, including immune cells. Cancer-immune communications critically shape antitumoral immunity, so defining which signals favour or disfavour an antitumour response is important for understanding cancer biology and therapy response.

The Mezzadra laboratory develops new approaches for studying cancer-immune crosstalks. We apply these tools to understand how signals originating from cancer cells treated with anticancer therapies alter the recruitment and function of intratumoral immune cells.

A man with short dark hair and a beard wearing a white lab coat.
A blue pencil icon tilted diagonally, drawing a horizontal line on a plain light grey background.

Biography

click here to read
Blue icon of a document with horizontal lines representing text and a folded bottom right corner, on a light grey background.

Recent Publications

click here to read

Biography

Education and qualifications

  • 2019: PhD, Leiden University Medical Center, Supervisor Ton N.M. Schumacher
  • 2010: M.Sc., Medical, Molecular and Cellular Biotechnology, Vita-Salute San Raffaele University
  • 2007: B.Sc, Medical and Pharmaceutical Biotechnology, Vita-Salute San Raffaele University

Appointments

  • 2027: Group Leader, Cancer Research UK Scotland Institute
  • 2019-2027: Postdoctoral Fellowship, Dr. Scott Lowe Lab, Memorial Sloan-Kettering Cancer Center
  • 2018-2019: Graduate Research Assistant, Prof. Ton Schumacher Lab, The Netherlands Cancer Institute

Honours and Awards

  • 2027: CRUK Career Development Fellowship
  • 2022-2025: Fellow of the MSK Society
  • 2024: Founders Fellow Award for the Aspen Cancer Conference
  • 2021: Irvington Postdoctoral Fellowship Program
  • 2019: Rubicon Postdoctoral Fellowship

Recent Publications

2025

Millman SE, Chaves-Perez A, Janaki-Raman S, Ho YJ, Morris JPt, Narendra V, et al. α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia. Blood 2025;145(13):1422-36 doi 10.1182/blood.2024025245.

Marasco M, Kumar D, Garcia Borrego S, Seale T, Maddalena G, Mezzadra R, et al. Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. Cancer Discov 2025;15(7):1392-409 doi 10.1158/2159-8290.Cd-24-0614.

Broderick C*, Mezzadra R*, Sisso EM, Mbuga F, Raghulan R, Chaves Perez A, et al. A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in PDAC. Cancer Discov 2025 doi 10.1158/2159-8290.Cd-24-1425.

2024

Pratt EC, Mezzadra R, Kulick A, Kaminsky S, Samuels ZV, Loor A, et al. uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence. J Nucl Med 2024;65(11):1718-23 doi 10.2967/jnumed.124.268278.

Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging 2024;4(3):336-49 doi 10.1038/s43587-023-00560-5.

2023

Yaeger R, Mezzadra R, Sinopoli J, Bian Y, Marasco M, Kaplun E, et al. Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer. Cancer Discov2023;13(1):41-55 doi 10.1158/2159-8290.Cd-22-0405.

Miao B*, Hu Z*, Mezzadra R*, Hoeijmakers L*, Fauster A, Du S, et al. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. Cancer Cell 2023;41(10):1817-28.e9 doi 10.1016/j.ccell.2023.08.008.

Chen HA, Ho YJ*, Mezzadra R*, Adrover JM, Smolkin R, Zhu C, et al. Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity. Cancer Discov 2023;13(2):432-53 doi 10.1158/2159-8290.Cd-22-0528.

2022

Ghosh A*, Michels J*, Mezzadra R, Venkatesh D, Dong L, Gomez R, et al. Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. J Clin Invest 2022;132(18) doi 10.1172/jci148141.

2020

Ruscetti M*, Morris JPt*, Mezzadra R*, Russell J, Leibold J, Romesser PB, et al. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell 2020;181(2):424-41.e21 doi 10.1016/j.cell.2020.03.008.

2019

Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, et al. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. Cell 2019;178(3):585-99.e15 doi 10.1016/j.cell.2019.06.014.

Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med 2019;25(1):89-94 doi 10.1038/s41591-018-0266-5.

Mezzadra R*, de Bruijn M*, Jae LT, Gomez-Eerland R, Duursma A, Scheeren FA, et al. SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing. PLoS One 2019;14(2):e0212053 doi 10.1371/journal.pone.0212053.

2018

Sun C*, Mezzadra R*, Schumacher TN*. Regulation and Function of the PD-L1 Checkpoint. Immunity2018;48(3):434-52 doi 10.1016/j.immuni.2018.03.014.

2017

Mezzadra R*, Sun C*, Jae LT*, Gomez-Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 2017;549(7670):106-10 doi 10.1038/nature23669.

2016

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 2016;375(9):819-29 doi 10.1056/NEJMoa1604958.

Mezzadra R, Hollenstein A, Gomez-Eerland R, Schumacher TN. A Traceless Selection: Counter-selection System That Allows Efficient Generation of Transposon and CRISPR-modified T-cell Products. Mol Ther Nucleic Acids 2016;5(3):e298 doi 10.1038/mtna.2016.13.

2014

Linnemann C, Mezzadra R, Schumacher TN. TCR repertoires of intratumoral T-cell subsets. Immunol Rev 2014;257(1):72-82 doi 10.1111/imr.12140.

2012

Moiani A, Paleari Y, Sartori D, Mezzadra R, Miccio A, Cattoglio C, et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest2012;122(5):1653-66 doi 10.1172/jci61852.

2010

Roselli EA, Mezzadra R, Frittoli MC, Maruggi G, Biral E, Mavilio F, et al. Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med2010;2(8):315-28 doi 10.1002/emmm.201000083.

* shared autorship

Secret Link